Pharma: Page 2

Charged aerosol detection: Chromatographer's magical tool to unravel the invisible in biologics

The discovery and development of next generation therapeutics will drive the availability and use of Biologics to meet the unmet medical needs, never imagined before.

By Yena Patel, Sahil Shah and Bart Byczynski • Sept. 27, 2021

Insurers sue Merck for 'monopolistic scheme' to delay generics of blockbuster cholesterol drug

The suits allege an agreement between Merck and a generic manufacturer kept low-cost versions of the drugmaker's widely used Zetia off the market for years.

By Samantha Liss • Sept. 24, 2021

Explore the Trendline➔

Inside the race to bring coronavirus vaccines to the world

More than a dozen shots are cleared for use in some fashion around the world. Producing enough supply and addressing the spread of coronavirus variants are the next challenges. 

By BioPharma Dive staff

AstraZeneca strikes deal with university spinoff to turn RNA into drugs

The British drugmaker is investing in VaxEquity, a biotech founded last year to explore a twist on the mRNA technology that Moderna and BioNTech have made famous.

By Ned Pagliarulo • Sept. 23, 2021

Chinese drugmaker Clover says vaccine prevents COVID-19 in large trial

Positive results from Clover's Phase 3 study could mean another coronavirus vaccine option for the many countries still grappling with short supplies.

By Jonathan Gardner • Sept. 22, 2021

US buying 500M more doses of Pfizer coronavirus vaccine for donation to world

Under pressure to help other countries access vaccines, Biden is doubling his administration's planned donation to 1 billion doses, although delivery will extend through September of next year. 

By Ned Pagliarulo • Sept. 22, 2021

Second dose of J&J's coronavirus vaccine increases protection, company says

Long-awaited results from a Phase 3 study run by J&J could support use of a booster dose, although the drugmaker has not officially applied for FDA clearance yet.

By Shoshana Dubnow • Sept. 21, 2021

Seagen, Genmab win speedy FDA approval for cervical cancer drug

Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.

By Jonathan Gardner • Sept. 21, 2021

Novartis pushes further into gene therapy for the eye with deal for Swiss startup

The large drugmaker has acquired Arctos Medical and its preclinical research into optogenetics, an area Novartis already showed interest in with its buyout of Vedere Bio last year.

By Ned Pagliarulo • UPDATED: Sept. 23, 2021 at 12:12 p.m.

Pfizer says coronavirus vaccine is safe and spurs immune response in children

The results position Pfizer and BioNTech to seek clearance in children as young as 5 years old. But the companies haven't yet shared data on a rare heart inflammation associated with their shot that's a concern for regulators.

By Jonathan Gardner • Sept. 20, 2021

ESMO21: Mirati sets new KRAS bar, AstraZeneca's breast cancer data and Keytruda challengers line up

Mirati's KRAS-blocking drug looks to have an edge over Amgen's, while AstraZeneca and Daiichi reported impressive data for their drug Enhertu.

By Ned Pagliarulo • UPDATED: Sept. 21, 2021 at 10:59 p.m.

Why 'hidden' thought leaders and their networks can make (or break) your launch

Finding the right thought leaders is not as simple as searching for KOLs or identifying high-volume prescribers.

By John Eichert, Senior Principal, Thought Leader Network CoE; Jennifer Millard, Vice President, Field Medical Affairs Deployment Services; and Bruce West, Senior Principal, Thought Leader Network CoE • Sept. 20, 2021

Takeda wins FDA approval for targeted lung cancer drug

Exkivity follows Johnson & Johnson's Rybrevant on the market for treating lung tumors harboring specific mutations in the EGFR gene. Unlike J&J's drug, however, Takeda's is given orally. 

By Kristin Jensen • Sept. 16, 2021

New data from Israel, Pfizer show potent effect from third coronavirus shot

The much-anticipated data arrive ahead of an important FDA advisory meeting to discuss authorization of a booster dose for Pfizer's coronavirus vaccine.

By Jonathan Gardner • Sept. 15, 2021

FDA staff tight-lipped on booster shot views ahead of consequential meeting

In a briefing document, agency reviewers did not appear to take a strong line either for or against the broad authorization of boosters for the general public.

By Shoshana Dubnow • Sept. 15, 2021

Overcoming inertia: Adopting omnichannel marketing for pharma

Pharmaceutical companies are increasingly attracted to the idea of replacing the current multichannel marketing focus with an omnichannel marketing approach. But the industry is struggling to break out of its own silos.

By Andrew Burkus, Principal, Omnichannel Marketing, IQVIA • Sept. 13, 2021

Biden pushes forward on Medicare price negotiation

But opposition from the drug industry and congressional Republicans could make the Democrats' signature proposal an uphill battle. 

By Jonathan Gardner • Sept. 10, 2021

Sanofi drug for rare skin disease, acquired in buyout, fails in late-stage trial

The French drugmaker bought Principia Biopharma last year for two therapies that block a protein called BTK. The second targets a much bigger disorder, multiple sclerosis.

By Jonathan Gardner • Sept. 09, 2021

Lilly joins RNA editing race with ProQR deal

An agreement with the Dutch biotech, which could be worth as much as $1.3 billion, expands Lilly's work in genetic medicine research.

By Kristin Jensen • Sept. 09, 2021

Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

Long a bystander in the race to develop so-called allogeneic treatments, the cancer drugmaking giant has joined the fray with a wide-ranging alliance that could be worth up to $3 billion.

By Jonathan Gardner • Sept. 07, 2021

Over-the-counter drug product monographs: What you need to know

Register for our OTC-focused webinars to get a deeper look at  five OTC drug monographs.

Settling lawsuit, AstraZeneca and European Commission agree on coronavirus vaccine delivery

The U.K.-based drugmaker fell behind on its promise to supply 300 million doses by the end of June to countries in the trading bloc. Now, it's set to reach that target by March 2022.

By Jonathan Gardner • Sept. 03, 2021

FDA panel to discuss boosters as Moderna seeks OK for additional shot

The advisory committee will meet Sept. 17 to weigh an additional dose of Pfizer's shot, just three days before the Biden administration aims to broadly roll out boosters to Americans. 

By Shoshana Dubnow • Sept. 02, 2021

Pfizer, marking fast research pace, starts key trial of RSV vaccine

The pharma company is in a tight race with rivals, including GSK, to become the first with an approved shot for the infectious disease.

By Kristin Jensen • Sept. 02, 2021

Novartis finalizes deal to make new heart drug widely available in England

An agreement between Novartis and England's national health system is an important commercial step for Leqvio, the cholesterol-lowering medicine the Swiss drugmaker acquired in its $10 billion buyout of The Medicines Co.

By Shoshana Dubnow • Sept. 01, 2021

Pfizer, Merck launch large new trials of oral COVID-19 drugs

Both companies are racing to prove their oral antivirals as treatments for COVID-19. Key clinical results could come later this year.

By Kristin Jensen • Sept. 01, 2021